NCNA vs. EFTR, ADXN, OBSV, BNOX, CYCN, VIRI, CMMB, TENX, GRAY, and ASLN
Should you be buying NuCana stock or one of its competitors? The main competitors of NuCana include eFFECTOR Therapeutics (EFTR), Addex Therapeutics (ADXN), ObsEva (OBSV), Bionomics (BNOX), Cyclerion Therapeutics (CYCN), Virios Therapeutics (VIRI), Chemomab Therapeutics (CMMB), Tenax Therapeutics (TENX), Graybug Vision (GRAY), and ASLAN Pharmaceuticals (ASLN). These companies are all part of the "pharmaceutical preparations" industry.
eFFECTOR Therapeutics (NASDAQ:EFTR) and NuCana (NASDAQ:NCNA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, community ranking, profitability, dividends, earnings and media sentiment.
57.7% of eFFECTOR Therapeutics shares are held by institutional investors. Comparatively, 44.0% of NuCana shares are held by institutional investors. 8.4% of eFFECTOR Therapeutics shares are held by insiders. Comparatively, 31.2% of NuCana shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
NuCana has lower revenue, but higher earnings than eFFECTOR Therapeutics. NuCana is trading at a lower price-to-earnings ratio than eFFECTOR Therapeutics, indicating that it is currently the more affordable of the two stocks.
NuCana received 225 more outperform votes than eFFECTOR Therapeutics when rated by MarketBeat users. However, 79.31% of users gave eFFECTOR Therapeutics an outperform vote while only 67.57% of users gave NuCana an outperform vote.
In the previous week, eFFECTOR Therapeutics had 1 more articles in the media than NuCana. MarketBeat recorded 1 mentions for eFFECTOR Therapeutics and 0 mentions for NuCana. NuCana's average media sentiment score of 0.00 equaled eFFECTOR Therapeutics'average media sentiment score.
eFFECTOR Therapeutics has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500. Comparatively, NuCana has a beta of 1.03, indicating that its share price is 3% more volatile than the S&P 500.
eFFECTOR Therapeutics currently has a consensus target price of $24.00, suggesting a potential upside of 1,070.73%. NuCana has a consensus target price of $125.00, suggesting a potential upside of 3,491.95%. Given eFFECTOR Therapeutics' higher possible upside, analysts clearly believe NuCana is more favorable than eFFECTOR Therapeutics.
NuCana's return on equity of 0.00% beat eFFECTOR Therapeutics' return on equity.
Summary
NuCana beats eFFECTOR Therapeutics on 7 of the 13 factors compared between the two stocks.
Get NuCana News Delivered to You Automatically
Sign up to receive the latest news and ratings for NCNA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NCNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
